Profile Picture
Rewards
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
    • Real Estate
    • My Bing
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

Attends NY civil fraud trial
UNLV shooting suspect
'Life Goes On' star dies
Shows up to support Stone
Retires after 18-year career
Stewart to replace wife Pruett
Sued over pizzeria crash
‘Mr. & Mrs. Smith’ trailer
Announce joint tour
‘I loved him dearly’
Suing Hauser over coffee
To host IA, NH debates
Fake aircraft parts scandal
Reaches 3,000 career points
Seasons 3, 4 in the works
‘The Brothers Sun’ trailer
N. Koreans deported by CN?
To get early release
4-year, $80 million deal
China's exports grow
British poet, activist dies
Dončić makes NBA history
Reality show winner revealed
AI powered image generator
FR to ramp up hotel checks
Wray to visit India next week
Pearl Harbor Day
US weekly jobless claims rise
Tomlin dismissed from team
Washington Post strike
Season-high 50 points
Reds sign Jeimer Candelario
Merger deal approved
Caprio diagnosed with cancer
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
5,200 results
Proactiveinvestors28d
AstraZeneca faces lawsuits in High Court over ‘defective’ Covid-19 vaccine
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...
The Motley Fool20d
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
AstraZeneca is making another go at developing a medicine like Ozempic. The U.K. pharma giant purchased licensing rights to a candidate in early-stage clinical trials. But that drug will need ...
Reuters23d
AstraZeneca's Imfinzi plus chemoradiotherapy fail main goal of late stage trial
Nov 14 (Reuters) - Drugmaker AstraZeneca (AZN.L) said on Tuesday its cancer drug Imfinzi given along with chemoradiotherapy (CRT) failed to meet its main goal in a late-stage trial to treat ...
Hosted on MSN28d
AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill—As Weight Loss Drug Market Grows
AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes—the latest pharmaceutical firm to bet on treatment similar to popular weight ...
Hosted on MSN28d
AstraZeneca CEO Pascal Soriot: Treatment of cancer in the last few years has been 'remarkable'
AstraZeneca CEO Pascal Soriot discusses Q3 earnings, oncology revenue, gene therapy treatments, what's to come for the company and the U.S. supply chain. Donald Trump Being Kicked off 2024 Ballot ...
The Financial Times28d
AstraZeneca signs deal for oral obesity drug and lifts profit outlook
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca is to enter the race for a weight loss pill, working on a next-generation class of drugs that ...
Wall Street Journal28d
AstraZeneca Raises Core EPS Guidance Despite Profit Miss
AstraZeneca raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines despite a lower third-quarter profit that missed forecasts after booking a tax ...
MarketWatch28d
AstraZeneca Shares Rise After Guidance Increase
Shares of AstraZeneca rose as much as 4.2% in early trade after the company raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines after beating ...
Morningstar3d
AstraZeneca PLC ADR AZN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Proactive Investors28d
AstraZeneca faces lawsuits in High Court over ‘defective’ Covid-19 vaccine
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices